

SmartHealth®

Provider Newsletter, June 2022

This newsletter shares important updates, reminders and resources related to the Ascension SmartHealth medical plan

Prior authorization update

All physician administered specialty medications or infusion therapies are subject to precertification notification or prior authorization (PA) approval. Beginning August 1, 2022, the following products will require PA approval:

- AVASTIN* bevacizumab (*reference biological, biosimilar does not require PA)
- CINQAIR reslizumab
- ENBREL** etanercept (**if being administered by physician in office)
- EPOGEN* epoetin alfa (*reference biological, biosimilar does not require PA)
- FASENRA benralizumab
- HERCEPTIN* trastuzumab (*reference biological, biosimilars do not require PA)
- HERCEPTIN HYLECTA trastuzumab / hyaluronidase-oysk
- KEYTRUDA pembrolizumab
- LUCENTIS ranibizumab
- NEULASTA* pegfilgrastim, (*reference biological, biosimilars do not require PA)
- NEUPOGEN* filgrastim (g-csf), (*reference biological, biosimilars do not require PA)
- NUCALA mepolizumab
- OPDIVO nivolumab
- PHESGO pertuzumab / trastuzumab / hyaluronidase-zzxf
- PROCREDIT* epoetin alfa (*reference biological, biosimilar does not require PA)
- REMICADE* infliximab, (*reference biological, biosimilars do not currently require PA)
- RITUXAN* rituximab, (*reference biological, biosimilars do not currently require PA)
- RITUXAN HYCELA rituximab / hyaluronidase
- SUSTOL granisetron, extended-release
- TEPEZZA teprotumumab-trbw
- XGEVA denosumab
- XOLAIR omalizumab
- ZINPLAVA bezlotoxumab

For a list of all products requiring PA approval, [click here](#). The link associated with the brand name allows you to review the approved clinical criteria for use for each product. For a complete product list with current requirements (precertification or PA), see the "Precert + PA tab".

For additional information, see the provider section on mysmarthealth.org/pharmacy.

Enhanced disease management for diabetes available to SmartHealth members

SmartHealth is pleased to offer an Enhanced Disease Management (EDM) program to its members and dependents with diabetes. The program works in partnership with the member's primary care clinician to offer personalized and integrated care from a team of specialists, including care managers, pharmacists, and behavioral health specialists.

By working together across all points of care, we can help our members better self-manage their diabetes, while giving them the confidence they need to make informed choices regarding their health.

Led by Ascension's national care management team, the program can help members with:

- Understanding and adhering to their medications.
- Self-blood glucose monitoring.
- Recognizing the signs of low and high blood glucose levels.
- Nutrition coaching for carbohydrate counting and weight management.
- Scheduling their recommended annual screening for diabetic complications.
- Blood pressure and cholesterol management.
- Optimizing their physical activity levels to meet recommended guidelines; and more.

The program is available at no extra cost and is included as part of the member's SmartHealth medical plan.

If you have a SmartHealth patient with diabetes who you feel could benefit from the EDM program, please refer them by calling 855-288-6747.

Payment for multiple procedures

SmartHealth follows CMS guidelines to pay for multiple surgical procedures performed by a single physician or physicians in the same group practice on the same patient at the same operative session or on the same day. SmartHealth pays for multiple surgeries by ranking from the highest contracted amount to the lowest contracted amount. When the same physician performs more than one surgical service in the same session, the allowed amount is 100% for the surgical code with the highest contracted amount. For subsequent surgical codes, the allowed amount is 50% of the contracted amount.

For additional information, refer to your provider manual.

COVID-19 temporary plan changes extended

SmartHealth has extended the Covid -19 temporary plan changes through 7/16/2022. (This date could change if the public health emergency is extended.)



